ID H0899

Establishes a pilot program within the Idaho Department of Health and Welfare to allow supervised therapeutic use of psilocybin, MDMA, and ibogaine for treatment of PTSD, major depressive disorder, substance use disorder, and other serious behavioral health conditions.

Limits initial eligibility to Idaho residents age 21 and older who are veterans, first responders, or individuals suffering from addiction, with mandatory screening and approval required before participation.

Requires all approved medicines to be administered only during supervised sessions; unsupervised use is prohibited, and the department must establish rules for secure storage, inventory controls, and diversion prevention.

Creates the MAHA Fund in the state treasury, funded through licensing fees, per-session fees, and voluntary grants/donations rather than ongoing general fund appropriations, with the program designed to operate revenue-neutral.

Mandates annual reporting to the governor and legislature beginning one year after services commence, covering participant numbers, session types, safety outcomes, clinical results, and program finances, with all rules subject to legislative approval.